Pfizer Ltd. — Board/Management Information 2023

Feb 9, 2023

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

==> picture [100 x 41] intentionally omitted <==

February 9, 2023

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J. Towers Exchange Plaza, 5th Floor, G Block Dalal Street, Fort Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sir,

Subject: Press Release

(DIN: 08235844) as an Additional Director and Managing Director of the Company for a period of 5 years with effect from April 3, 2023.

Request you to take the same on record.

Thanking you,

Yours truly,

For Pfizer Limited

PRAJEET NAIR

Digitally signed by PRAJEET NAIR DN: c=IN, o=Personal, 2.5.4.20=9933a48702916ad69ca05ea07b057e4a4737e501e65 094b9d54663b70517bbe5, postalCode=400054, st=MAHARASHTRA, serialNumber=c24aea3eb0ba76c8cf19782a6242b9b35252d6 b9461f59c3998022881b762db1, cn=PRAJEET NAIR, l=MUMBAI, title=7345, pseudonym=734520210415120738822, email=PRAJEET.NAIR@PFIZER.COM Date: 2023.02.09 17:38:46 +05'30'

Prajeet Nair Director – Corporate Services & Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

==> picture [84 x 35] intentionally omitted <==

Pfizer Limited announces the appointment of Meenakshi Nevatia as the Managing Director and Additional Director, effective 3[rd] April,2023

Mumbai, INDIA, 9[th] February 2023: Pfizer Limited announced that its Board of Directors has appointed Meenakshi Nevatia as an Additional Director and the Managing Director for a period of five years with effect from 3[rd] April 2023. She succeeds S.Sridhar, who announced his early retirement in August 2022.

Meenakshi is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and more recently with Stryker Corporation. Meenakshi has worked in over 8 countries (developed and emerging) and has held several General Management roles across multiple markets such as Thailand, Spain (Iberia) and India.

Meenakshi received her Bachelor’s in Science (Economics) from Presidency College, Kolkata, India and completed her Post Graduate Diploma in Management from the highly acclaimed Indian Institute of Management Ahmedabad (IIMA).

On this important Leadership appointment Mr. Pradip Shah, Chairman of the Board, Pfizer Limited said “ This is a pivotal time for Pfizer in India, and I am pleased to welcome Meenakshi to take over the baton and set new benchmarks for the company and indeed the industry, I also wish to express my gratitude to Sridhar for his long years of service. His patient-centric vision contributed significantly to the growth of the company, increasing our reach to many more patients in the country and helping them benefit from the company’s drugs and therapies over the years. ”

Nick Lagunowich, Global President, Emerging Markets Pfizer said, “ India is critical to the healthcare ecosystem in the region and globally; it is a place where we aspire to bring many more breakthrough therapies and health solutions to patients across the economic segments. We are thrilled to welcome Meenakshi who comes at an important time when we are poised to scale up our contribution to the India Healthcare industry .”

The Board of Directors of Pfizer Limited, at their meeting held on 9[th] February 2023, considered the recommendation of the Nomination & Remuneration Committee, and approved the appointment of Meenakshi as the Managing Director w.e.f. 3[rd] April 2023. S. Sridhar the current India Country President will be stepping down as Managing Director and Member of Board close of business hours on 31[st] March 2023.

The appointment of Meenakshi will be subject to approval of shareholders through Postal Ballot and central government.

About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and

local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizerindia.com.

Pfizer Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.

Media contact:

Chikita Sobti | + 91 98201 91347 | Chikita.sobti@pfizer.com